Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

What Was Tested

In this not phased trial, researchers set out to test Neurotensin.

Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.

It had four arms (groups): Saline+Saline (other), Neurotensin+Saline (other), GLP-1+Saline (other) and Neurotensin + GLP-1 (other).

The registry classes the interventions as other.

Who Took Part

Enrollment: 35 planned participants were the target.

It was open to men only aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Above 18 years of age. Normal hemoglobin concentration.

The full record lists 4 inclusion and 9 exclusion criteria; among the exclusions: diabetes mellitus; truncal vagotomy; resection of intestine (apart from appendectomy).

How the Study Was Run

It was run as a randomized, crossover and double-blind study.

The participants were allocated by chance, so the Neurotensin group and the comparison group should start out alike.

Each person switched between Neurotensin and the comparison at some point, usually with a gap in between.

As a double-blind Neurotensin study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2019-10-01 with completion listed for 2024-06-10.

It ran at 2 sites in Denmark (2).

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Ad-libitum food intake (time frame: 120 min).

It also tracked 12 secondary outcomes, for example Appetite and gastrointestinal sensations, Plasma glucose, Neurotensin, GLP-1, Insulin and C-peptide.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Neurotensin in 35 people.

Its size is small, so on its own it can only give an early look.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Neurotensin compound page, all human trials.